한국어
Quantus

National Research

NRC · Nasdaq
$21.53+1.32%
2026-09-04 close

National Research last closed at $21.53 (+1.32%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…
Close
Super Strong RS 88 · top 12%

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Signal history

DateSignal+20 trading days

A record, not a prediction.

How this is calculated

"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

C
Overall: 상사,자본재 152/197 · top 77%
Factor composite · relative position in sector

PER 23.35 · PBR 18.5 — own-history percentile 82/100 · 22/100

Open self-history band
PER82/100
PBR22/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2015: $0.2420152016: $0.682017: $0.402018: $0.542019: $1.262020: $0.4220202021: $0.362022: $0.842023: $1.482024: $0.482025: $0.48$0.482025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
B-
Growth
F
Yield
B-
Safety
C+
Reference indicatorView observed cut rates

Paid 11 consecutive years · Raised 0 consecutive years · Yield 2.23% (based on 2025 payment of $0.48) · 3-year growth -17.0%

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 0.88
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
0.88
Beneish M-Score
-2.96

No statistical flag

Sloan accrual
-7.43%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 하락 → 마진 압박 → 현금 악화

Critical

매출이 -3.7% 감소하며 영업이익률이 27.0%에서 24.6%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.

Evidence

매출 YoY -3.7% (2023→2024)영업이익률 27.0%→24.6%영업CF 38→35

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

USAs of 2026-09-05

상사,자본재

This stock is in 상사,자본재: revenue rank 140 of 186, share 0%.

140 / 1860%revenue share

Who dominates this industry?

  1. 1Raytheon Technologies9.2%
  2. 2Lockheed Martin8.1%
  3. 3Boeing7.6%
  4. 4General Dynamics5.4%
  5. 5Northrop Grumman4.7%
  6. 6National Research0%

Concentration

DistributedCR3 24.9%
HHI 358186 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

MixedConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
11.85
Direction
확대
Level
보통
Years
10

Value lens

P90/P10
22.7
Median P/B
3.43
Level
넓음
n
172

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
24.6%
Interest coverage
13.6x
Return on equity (ROE)
79.2%

Operating margin −5pp

Tolerable
Interest coverageBase 13.6x adverse case 10.8x
Return on equity (ROE)Base 79.2% adverse case 81.3%

Revenue −15%

Tolerable
Interest coverageBase 13.6x adverse case 11.5x
Return on equity (ROE)Base 79.2% adverse case 87.3%

Interest rate +2pp

Tolerable
Interest coverageBase 13.6x adverse case 7.6x
Return on equity (ROE)Base 79.2% adverse case 97.7%

Interest coverage limit

Current margin 22.8pp

Interest coverage limit at an operating margin of 1.8%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

Same theme
Clinical Research Holdings
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About National Research
What technical signals does National Research (NRC) have?
National Research current technical signals: no active technical signal.
Is National Research a cup-and-handle pattern?
No. National Research has no valid cup-and-handle signal right now.
What are National Research's financials and valuation?
National Research's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy